Status:
RECRUITING
The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
Lead Sponsor:
Ningbo Medical Center Lihuili Hospital
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to learn about Drug loaded microspheres for bronchial artery chemoembolization (DEB-BACE) combined with anlotinib and adebelimumab in patients with advanced NSCLC af...
Eligibility Criteria
Inclusion
- Age\>18 years old, gender unlimited;
- According to the Diagnosis and Treatment Guidelines for Primary Lung Cancer (2018 Edition), NSCLC was diagnosed by pathological histology;
- TNM staging is III - IV;
- Failure of second-line treatment according to the CSCO guidelines;
- ECOG PS score ≤ 2 points;
- Estimated survival time\>3 months;
- Sign informed consent form
Exclusion
- Individuals who have previously received interventional therapy (iodine particle implantation, ablation, BACE treatment), or have received PD-L1 inhibitor immunotherapy during the first or second line standard treatment period of the patient;
- Patients with other malignant tumors that have not been cured;
- White blood cells\<3 × 109/L, absolute value of neutrophils\<1.5 × 109/L, neutrophil/lymphocyte ratio ≥ 3, platelet count\<50 × 109/L, hemoglobin concentration\<90 g/L;
- Liver and kidney dysfunction (creatinine\>176.8) μ Mol/L; Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)\>twice the normal upper limit;
- Central squamous cell carcinoma with cavity features;
- Incorrectable coagulation dysfunction or concomitant active massive hemoptysis;
- Patients with concurrent active infections who require antibiotic treatment;
- Uncontrollable hypertension, diabetes, and cardiovascular diseases with obvious symptoms;
- Contrast agent allergy;
- Women with concurrent pregnancy or lactation
Key Trial Info
Start Date :
December 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06188650
Start Date
December 9 2023
End Date
September 30 2026
Last Update
January 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaitai Liu
Ningbo, Zhejiang, China, 315040